Safe Biologics

DECEMBER 8, 2022

ASBM Advisory Board Chair Philip Schneider, MS, FASHP, FFIP gave a presentation entitled “Key Factors for Improving Sustainability in Biosimilar Markets”. The presentation reflected the findings from a recent webinar ASBM held on this subject with GaBI Journal. Read the GaBI Journal report of the webinar here.

Biosimilars 100

Biosimilars Communication Drug Development 100

pharmaphorum

JUNE 17, 2025

billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

pharmaphorum

JUNE 10, 2025

Skip to main content Tuesday 10 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 85

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 85

Pharma Marketing Network

FEBRUARY 27, 2025

For example, a pharma company launching a new biosimilar for rheumatoid arthritis can publish a whitepaper detailing clinical comparisons with the branded biologic. Webinars & Virtual Conferences HCPs value expert insights and peer discussions. Behind-the-scenes research lab videos showcasing drug development.

Biosimilars 52

Biosimilars Communication Diabetes Drug Development 52

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Safe Biologics

OCTOBER 10, 2023

Department of Health and Human Services​ Clip 2: Drug Developer Discusses Impacts on R&D – Steven Potts, PhD, MBA – View clip Clip 3: Innovation and Patient Access – Andrew Spiegel, Esq. Clip 4: Panel Discussion – View clip. Full Webinar – View the full webinar here. FDA Approves First U.S.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Pharmacy Times

JUNE 19, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Compounding Pharmacies 26

Safe Biologics

SEPTEMBER 11, 2023

On July 26 th , ASBM hosted a webinar with the Generics and Biosimilars Initiative (GaBI) to examine the price-setting policy’s impact on drug development and reduced patient access to new medicines.

Drug Pricing 150

Drug Pricing Biosimilars Drug Development Vaccines 150

Big Molecule Watch

MARCH 12, 2025

With 10 years of litigation since the first BPCIA complaint on NEUPOGEN (filgrastim) was filed in 2014, trends are becoming apparent that should cause all biopharma companies to reassess how they protect biologics and plan for biosimilar launch.

Biosimilars 52

Biosimilars Drug Development 52